Clinical Data Obtains Viibryd Approval In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Massachusetts-based biotech Clinical Data has gotten approval from FDA to bring its first product to market, an antidepressant called Viibryd that it in-licensed from Merck KGaA.
You may also be interested in...
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.
MDD Market Snapshot: Depressing Future For Antidepressants
Although a significant portion of the U.S. population – approximately 6.5% or 15 million adults annually – suffers from depression, the antidepressant drug market is on the decline and sales are expected to decrease further over the next two years as two of the largest products on the market, Forest Laboratories’ Lexapro (escitalopram) and Eli Lilly & Co.’s Cymbalta (duloxetine), face patent expirations.
Forest Launching Two New Drugs Before Life After Lexapro
The specialty pharmaceutical company talks about plans for launching two new products as it prepares to face generic competition for its largest revenue driver.